Blood

Vol. 146, Issue 14 Issue 14 2025
16
Articles

Articles in this Issue

The endothelial mTORC2-Foxo1 axis serves as an iron-responsive sensor governing systemic iron homeostasis

Wenting Zhao, Peina Wang, Zhengxun Liu et al. Oct 02, 2025 pp. 1722-1736 10.1182/blood.2025028454

Abstract Liver sinusoidal endothelial cells (LSECs) are essential for maintaining liver function by actively sensing nutrients and producing angiocrine factors. LSECs also regulate s...

Rebalancing the hemophilia teeter-totter

Thomas C. Abshire Oct 02, 2025 pp. 1631-1632 10.1182/blood.2025030260

A new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification

Julia J. Scarisbrick, Pietro Quaglino, Sean Whittaker et al. Oct 02, 2025 pp. 1687-1692 10.1182/blood.2025029628

Abstract Advanced mycosis fungoides (MF) and Sézary syndrome (SS) have a poor overall survival (OS) of <5 years. Studies have found the current staging (IA-IVB) is inadequate...

How I treat pediatric pulmonary embolism

Ayesha Zia, Neil A. Goldenberg, Madhvi Rajpurkar Oct 02, 2025 pp. 1643-1653 10.1182/blood.2024026599

Abstract Venous thromboembolism (VTE) affects ∼1 in 200 hospitalized children. The diagnosis of pulmonary embolism (PE), the most severe clinical presentation of VTE, has increased d...

AML halts neutrophil maturation

Lakshmi Sandhow, Diana Passaro Oct 02, 2025 pp. 1638-1639 10.1182/blood.2025030403

Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST

Maximilian Merz, Nico Gagelmann, Samih Smaili et al. Oct 02, 2025 pp. 1677-1686 10.1182/blood.2025028330

Abstract Cellular therapies targeting B-cell maturation antigen have shown promise in controlled clinical trials, but their impact in broader, diverse patient populations remains und...

Marstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial

Davide Matino, Andrew Palladino, Carrie Turich Taylor et al. Oct 02, 2025 pp. 1654-1663 10.1182/blood.2024027468

Abstract Marstacimab targets the tissue factor pathway inhibitor to rebalance hemostasis. Previous phase 1 and 2 trials established marstacimab safety and efficacy in adults with sev...

Foxo1 unlocks the liver endothelial code to iron sensing

Kostas Pantopoulos Oct 02, 2025 pp. 1639-1641 10.1182/blood.2025030281

More than skin deep

Ryan A. Wilcox Oct 02, 2025 pp. 1635-1636 10.1182/blood.2025030356

CAR-DLI for ALL, but not without lymphodepletion

Lutz P. Müller Oct 02, 2025 pp. 1632-1634 10.1182/blood.2025030291

IPSS-M risk and specific sex-associated somatic mutations predict response to ESA therapy in LR-MDS: building a new score

Marco G. Raddi, Sophie Park, Michaela Fontenay et al. Oct 02, 2025 pp. 1693-1706 10.1182/blood.2024027540

Abstract Acquired somatic mutations are incorporated in the classification and prognosis of myelodysplastic syndromes/neoplasms (MDSs). However, the predictive role of molecular feat...

The acute myeloid leukemia microenvironment impairs neutrophil maturation and function through NF-κB signaling

Paran Goel, Sajesan Aryal, Alana M. Franceski et al. Oct 02, 2025 pp. 1707-1721 10.1182/blood.2024028199

Abstract Acute myeloid leukemia (AML), an aggressive hematological malignancy, is driven by oncogenic mutations in stem and progenitor cells that give rise to AML blasts. Although th...

In low-risk myelodysplastic syndrome, don’t shoot the <i>STAG2</i>

Natasha Szuber, Lambert Busque Oct 02, 2025 pp. 1636-1638 10.1182/blood.2025030114

Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion

Claire Roddie, Juliana Dias, Maeve A. O’Reilly et al. Oct 02, 2025 pp. 1664-1676 10.1182/blood.2025028790

Abstract We developed an allogeneic matched donor CD19 chimeric antigen receptor (CAR) product (CAR–donor lymphocyte infusion [DLI]) for adult patients with B-cell acute lymphoblasti...

AML with mutated TP53, therapy-related, with basophilic differentiation, partial CD22, and ring sideroblasts

Zhaodong XU, Eric McGinnis Oct 02, 2025 pp. 1737-1737 10.1182/blood.2025029483

DRiving STandard-of-care CAR T cells in real-world Germany

Mark R. Dowling, Simon J. Harrison Oct 02, 2025 pp. 1634-1635 10.1182/blood.2025029932

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page